SG Americas Securities
CUE icon

SG Americas Securities’s Cue Biopharma CUE Stock Holding History

SG Americas Securities’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-364
Closed -$159K – 3457
2021
Q3 		$159K Buy
+364
New +$127K ﹤0.01% 3388
2020
Q4 		– Sell
-548
Closed -$247K – 3355
2020
Q3 		$247K Buy
548
+327
+148% +$188K ﹤0.01% 2034
2020
Q2 		$162K Sell
221
-25
-10% -$18.1K ﹤0.01% 3027
2020
Q1 		$105K Buy
+246
New +$119K ﹤0.01% 2968

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

SG Americas Securities's CUE Position: Q4 2021 in Review

SG Americas Securities sold out of Cue Biopharma (CUE) in Q4 2021, closing a stake of 364 shares — an estimated $159K sold.

SG Americas Securities first reported a position in CUE in Q1 2020 and held it in 4 quarters. The position peaked at $247K in Q3 2020. 90 funds tracked by Wall St. Rank hold CUE as of Q4 2021.

  • SG Americas Securities reported no remaining Cue Biopharma position as of Q4 2021 after selling out during the quarter.
  • SG Americas Securities sold 364 Cue Biopharma shares in Q4 2021, an estimated $159K.
  • SG Americas Securities first reported a position in Cue Biopharma in Q1 2020 and held it in 4 quarters.
  • SG Americas Securities's Cue Biopharma position peaked at $247K in Q3 2020.
  • 90 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.